# US 2021/0172948 A1 · Method for detecting bacteria according to the gram signal thereof in a complex sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172948 A1
- Document ID: US20210172948A1
- Status: Published application
- Kind: A1
- Application number: 17/253,613
- Filed: 2019-06-13
- Published: 2021-06-10
- Earliest claimed: 2018-06-18
- Assignees: Maat Pharma; Bioaster
- Applicants: MaaT PHARMA; Bioaster
- Inventors: Aurore DUQUENOY; Samuel BELLAIS; Vincent THOMAS
- Web page: https://patentgrep.com/patent/US20210172948A1

## CPC

- G01N 33/56911: {Bacteria}
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 2333/4724: Lectins
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a method for detecting the proportion of Gram-positive and Gram-negative bacteria in a complex sample. The bacteria are detected according to the Gram signal thereof. The invention enables distinction between species of Gram-positive bacteria and species of Gram-negative bacteria in a complex sample. The invention also relates to a kit for marking Gram-positive and Gram-negative bacteria, particularly for use in flow cytometry, particularly for complex samples such as human or animal microbiota samples.

## Claims

### Claim 1

A method for detecting, in a sample containing bacteria, the proportion of Gram-positive bacteria and the proportion of Gram-negative bacteria, comprising the steps of:
a) incubating the sample, simultaneously or sequentially, with:
wheat lectin (WGA) coupled to a fluorochrome,
vancomycin coupled to a fluorochrome emitting a fluorescence at a different wavelength from the fluorochrome coupled to WGA,
optionally vancomycin that is not coupled to a fluorochrome,
optionally potassium chloride,
b) centrifuging the sample,
c) optionally washing the sample, and
d) measuring the fluorescence of the sample using flow cytometry.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fluorochrome coupled to WGA is Alexa Fluor® 647 and the fluorochrome coupled to vancomycin is 3-BODIPY-propanoic acid.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the measurement step is carried out in less than 40 minutes after the end of step c).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the measurement step d) is carried out with a flow cytometer.

### Claim 5 (depends on 1)

The method according to claim 1, wherein, in step a), the concentration of the wheat lectin (WGA) coupled to a fluorochrome in the sample to be analyzed is from 5 to 100 μg/ml, and/or the final concentration of the vancomycin coupled to a fluorochrome in the sample to be analyzed is from 0.15 to 4 μg/mL.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the incubation time in step a) is from 10 to 30 minutes.

### Claim 7 (depends on 1)

The method according to claim 1, wherein that the sample is a sample of human or animal microbiota.

### Claim 8

A method for detecting, optionally distinguishing and identifying families, genera and/or species of Gram-positive bacteria and Gram-negative bacteria in a bacterial sample, comprising the steps of:
a) incubating the sample, simultaneously or sequentially, with:
wheat lectin (WGA) coupled to a fluorochrome,
vancomycin coupled to a fluorochrome emitting a fluorescence at a different wavelength from the fluorochrome coupled to WGA,
optionally vancomycin,
optionally potassium chloride,
b) centrifuging the sample,
c) optionally washing the sample,
d) measuring the fluorescence of the sample using flow cytometry,
e) analyzing the relative fluorescences of the two fluorochromes, and
f) optionally distinguishing and identifying families, genera and/or species of Gram-positive and Gram-negative bacteria.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the fluorochrome coupled to WGA is Alexa Fluor® 647 and the fluorochrome coupled to vancomycin is 3-BODIPY-propanoic acid.

### Claim 10

A kit comprising:
i. wheat lectin (WGA) coupled to a fluorochrome,
ii. vancomycin coupled to a fluorochrome emitting a fluorescence at a different wavelength from the fluorochrome coupled to WGA, and
iii. optionally vancomycin,
optionally potassium chlorid.

### Claim 11 (depends on 10)

The kit according to claim 10, wherein the fluorochrome is Alexa Fluor® labelling agent, 3-BODIPY-propanoic acid or one of its derivatives, fluorescein or one of its derivatives, salts or esters, a Cy labelling agent, a CF labelling agent, or a conjugated fluorochrome.

### Claim 12 (depends on 11)

The kit according to claim 11, characterized in that wherein the fluorochrome coupled to WGA is an Alexa Fluor® labelling agent, fluorescein or one of its derivatives, salts or esters.

### Claim 13 (depends on 11)

The kit according to claim 11, wherein the fluorochrome coupled to vancomycin is 3-BODIPY-propanoic acid or one of its derivatives, fluorescein or one of its derivatives, salts or esters.

### Claim 14 (depends on 11)

The kit according to claim 11, wherein the fluorochrome coupled to WGA is Alexa Fluor® 647 and the fluorochrome coupled to vancomycin is 3-BODIPY-propanoic acid.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the measurement step is carried out in less than 30 minutes.

### Claim 16 (depends on 1)

The method according to claim 1, wherein, in step a), the concentration of the wheat lectin (WGA) coupled to a fluorochrome in the sample to be analyzed is 20 μg/ml, and/or the final concentration of the vancomycin coupled to a fluorochrome in the sample to be analyzed is 2 μg/ml.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the incubation time in step a) is 15 minutes.

### Claim 18 (depends on 11)

The kit according to claim 11, wherein the fluorochrome coupled to vancomycin is FITC.
